Purpose: To present the clinical, radiological, histopathological, immunohistochemical features and the followup of orbital primitive neuroectodermal tumors (PNETs) in pediatric patients along with a review of the literature.
INTRODUCTION
Primitive neuroectodermal tumors (PNETs) are embryonal neoplasms that originate from the neural crest cells. 1 They are a heterogenous group of malignant neuroepithelial tumors having small round cells that occur mostly in children and young adults. Initially, it was believed that central the nervous system was the most common site of PNETs. However, because they were seen outside of the central nervous system, PNETs were reclassified as central PNET and peripheral PNET. Orbital PNET is a subtype of peripheral PNET. 2 Orbital PNET shows varying degrees of neural differentiation. Histopathology and radiological imaging are supportive of but not diagnostic for orbital PNET. Ultrastructural techniques and immunohistochemistry help to confirm the diagnosis of peripheral PNET. 3 Presence of peripheral PNET in the orbit is extremely rare and poses a diagnostic challenge. 4 Peripheral PNET is considered part of the Ewing sarcoma family of tumors, and shows an aggressive nature along with bony invasions and extraorbital extensions. 5 Orbital PNET should be managed by a combination of surgery, chemotherapy, and radiotherapy to prolong the survival rate. It is also advisable to observe these patients for life to rule out recurrence, metastasis, and treatment-related malignancies. 4 To the best of our knowledge, only 28 cases of primary orbital PNET have been reported in the international literature to date, 19 of which were children. 5 The current study reports four additional cases of orbital PNET in children and describes their clinical findings, radiologic features, histopathology, immunohistochemical analysis, management, and outcome along with a literature review of orbital PNET.
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PATIENTS AND METHODS
A retrospective analysis of all diagnosed cases of orbital PNET was done at Al Shifa Trust Eye Hospital, Pakistan, from 2005 to 2016. The study was approved by the Institutional Research Ethical Committee. A written informed consent was taken from the legally acceptable representative of the studied children and none of the studied patients received any stipend. Patients' demographic characteristics, ophthalmic findings, imaging, immunohistochemistry, metastatic work-up, treatment, globe salvation, and survival were documented and a mini literature review of orbital PNET was done. Complete remission, partial remission, and progression were diagnosed according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. 6 
RESULTS
Four cases of orbital PNET were diagnosed and treated during the study period. These patients presented to us with ophthalmic signs and symptoms and radiological imaging showed primary orbital involvement. There were three males and one female with a mean age of 63.75 months (range: 3 to 244 months).
Case 1 was a 3-month-old female infant who presented with forward and upward displacement of the left eye ball since birth. The rest of the eye examination was normal. Imaging showed a well-defined tumor along the floor of the orbit ( Figure 1A) . Through an anteroinferior approach, the well-defined tumor was removed in toto and histopathology and immunohistochemistry confirmed the diagnosis of PNET.
Case 2 was a 3-year-old boy who presented with left lateral and forward displacement of the globe over a period of 6 months along with loss of vision. The fundus examination revealed choroidal folds and pale optic disc. The child underwent left anteromedial orbitotomy and a firm, well-defined mass was removed from the medial half of the orbit. The mass was compressing and engulfing the optic nerve and medial rectus muscle (Figure 2A) .
Case 3 was a 12-year-old boy who presented with rapid forward and downward displacement of the left globe over a period of 2 months. It was associated with considerable pain. Computed tomography showed an ill-defined tumor of varying intensity in the superolateral part of the orbit with associated bone erosion ( Figure 3A) . The tumor was found to be vascular and ill defined and could be removed only in parts.
Case 4 was a 5-year-old boy who presented with the complaints of right lateral and forward displacement of the eyeball over a period of 3 months. A well- defined cylindrical mass was removed completely from the right medial orbit. The child underwent chemotherapy. The patient presented with recurrence of the orbital tumor after 1 year. The globe was displaced downward and forward and computed tomography scanning showed a tumor in the superomedial part of the right orbit with varying degrees of calcification ( Figure 4A ). There was also an associated tumor in the right frontal lobe. Through superomedial orbitotomy, an ill-defined tumor was removed and the child again underwent chemotherapy. Four years later, the child presented again with a mass in the opposite (left) orbit. The child was advised to have radiation and chemotherapy. However, the child was lost to follow-up.
Histopathology of all studied patients showed small round malignant cells with hyperchromatic nuclei and increased nuclear cytoplasmic ratio. The malignant cells were arranged in sheets and showed mitotic figures frequently ( Figures 1B, 2B , 3B, and 4B). Rosettes were not seen in any case. Sections were later studied by immunohistochemistry with synchronous application of the antibodies yielding positive control slides. In our cases, immunohistochemistry was positive for CD99 ( Figures 1C, 2C , 3C, and 4C) and FLI-1 ( Figures 1D, 2D, 3D , and 4D), with a high proliferative index revealed by Ki-67 staining. Immunohistochemistry for Periodic acid-Schiff stain, terminal deoxynucleotidyl transferase, desmin, actin, synaptophysin, leukocyte common antigen, and cytokeratin were negative in all cases, which ruled out other common differential diagnoses.
All four patients underwent orbital surgery for excision of tumors followed by chemotherapy. One of the patients also had external radiation in addition to chemotherapy after a second recurrence. The follow-up period of these patients varied from 1 to 5 years. Three of the children have not reported any recurrence so far. The fourth child who had recurrence twice was followed up to 5 years, but was lost to follow-up after that.
DISCUSSION
Bakhshi et al. presented the largest cases series of orbital PNET in children. 7 This is the second largest case series of orbital PNET in children ( Table 1) . To the best of our knowledge, only 28 cases of primary orbital PNET have been reported in the international literature to date, 19 of which were children 5 ( Table A , available in the online version of this article). The case of congenital orbital PNET of the current study (case 1) is perhaps the third case of congenital orbital PNET reported to date. 7 Peripheral PNET represents 4% to 17% of all soft tissue tumors in children. 8 Recent evidence claims that peripheral PNET and Ewing sarcoma are closely related to each other and represent likely manifestations of the same spectrum of disease. Degree of neural differentiation plays an important role in differentiating PNET from Ewing sarcoma, with the former showing evidence of neural differentiation and the latter being without it. 5 There has been speculation to explain the histogenesis of peripheral PNET. Shuangshoti et al. proposed that undifferentiated neuroepithelial cells diverge and extend from the neural tube to the peripheral tissues during embryological development and give rise to peripheral PNET. 9 On the other hand, Howard suggested that neuroepithelial cells migrate along with peripheral nerves and lead to the development of peripheral PNET. 10 The differential diagnosis of orbital PNET includes Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, mesenchymal chondrosarcoma, lymphoma, and osteogenic sarcoma. At times, it becomes difficult to differentiate peripheral PNET from other small, round cell tumors because they have some microscopic features and genetic abnormalities in common. 11 Small, round cells, hyperchromatic nuclei, and Homer-Wright rosettes are suggestive but not diagnostic of peripheral PNET. Peripheral PNET shows a varying degree of neural differentiation beginning with neuron-specific enolase expressivity, followed by Homer-Wright rosette formation, phenotypic ganglion cell differentiation, and neurofilament protein expression. 3 Homer-Wright rosettes were not seen in the patients of the current study.
Ultrastructural and/or immunohistochemical techniques help to determine neural differentiation, which plays a pivotal role in differentiating peripheral PNET from other similar tumors.
4 Translocation (11;22) (q24;q12) is the most common genetic mutation in peripheral PNET. 12 More than 85% of the cases of Ewing sarcoma/peripheral PNET show similar chromosomal rearrangements and are characterized by t(11;22) (q24;q12), which results in the fusion of the FLI-1 gene on chromosome 11q24 with the EWS gene on chromosome 22q12. Chokthaweesak et al. used RT-PCR and FISH to identify this rearrangement in tumor biopsy specimen of their studied patients. Peripheral PNET exhibits inconstant immunohistochemical features and can be positive for a wide range of neural markers, including vimentin, synaptophysin, S100, neuron-specific enolase, CD99 (MIC2 gene), neurofilaments, chromogranin, and CD57 (LEU-7/ HNK-1).
3,4 CD99, NSE, and S100 are the three immunohistochemical markers detected more commonly in the reported cases of orbital PNET in the pediatric age group, whereas adults showed positivity for CD99 and vimentin. 4, 5 The tumors were positive for CD99 and FLI-1 in all of the studied patients.
Of the 17 cases of orbital PNET discussed by Romero et al., ultrastructural techniques were used in 8 cases to either make a histopathological diagnosis or confirm immunohistochemistry results. 4 Although electron microscopy can be a useful aid in diagnosing peripheral PNET by showing cytoplasmic filaments, neurosecretory granules, microtubules, and synapticjunctions, 13 it was not available in the clinical setting of the authors of the current study.
Peripheral PNETs have an aggressive nature.
14 Primary orbital PNET is extremely rare and less aggressive than other forms of peripheral PNET. 4 Orbital peripheral PNETs show bony invasions and extraorbital extensions. 4, 10, 14, 15 In the study by Bakhshi et al., four cases had large tumors with extraorbital involvement without systemic metastasis. 7 The literature review of the 28 reported cases of orbital PNET showed 6 deaths related to orbital PNET and metastasis to liver and lungs was seen in just 2 reported cases of orbital PNET. The metastatic orbital PNET did not respond to further treatment. 5 One case had regional lymph node involvement. 4 In the current study, one patient had local recurrence and regional metastases twice (first to the brain after 1 year and second to the opposite orbit) over a period of 5 years, whereas chemotherapy was given twice and radiation once. The other three cases who underwent surgery and chemotherapy have not reported recurrence over a period of 18 months. None of the four cases had distant metastases. Because the orbit is generally believed to have a poor lymphatic system, this could be attributed to the lack of systemic metastasis seen in orbital peripheral PNET. 4 Bone marrow, bones, brain, lungs, and liver are probable sites of metastasis in orbital peripheral PNET. 4, 10, 16, 17 The literature review showed that orbital PNET has a propensity to involve the lateral wall. Eleven reported cases had involvement of the lateral wall of the 22 cases in which the site of the tumor was documented. The second common site was the superior wall of the orbit. All of the 28 reported cases presented with variable visual loss and unilateral proptosis that was progressive in nature and painless. In the current study, there were no specific topographic predilections. Two patients had medial orbital involvement, whereas one had orbital floor involvement and the fourth involved the superolateral part of the orbit.
Radiographically, orbital PNETs are heterogenous, variable enhancing tumors and do not show destructive features. 5 The right orbit was involved in most reported cases. Previously, calcification was not reported in orbital PNET. However, Bakhshi et al. came across small calcific densities in two cases and osseous cartilaginous matrix with spicules in one case. 7 In the current study, there was marked left-sided involvement and 3 of the 4 children had left orbital involvement. Case 3 had shown bone erosions at the time of presentation, whereas case 4 presented with calcification after local recurrence.
The best therapeutic strategy for peripheral PNET is still debatable. 18, 19 Surgery has been the initial treatment option in most cases of orbital PNET reported in the international literature and was also the treatment strategy used in all cases in the current study. Chemotherapy and radiotherapy without surgery have also shown promising results. 3, 14 Because it sometimes becomes difficult to remove the tumor in toto by surgery, chemotherapy with or without radiotherapy has been advocated as an appropriate additional treatment modality. 4 Peng et al. recommended that surgery plus systemic chemotherapy was an effective way to prolong survival in patients with peripheral PNET. 20 CAV/IE (cyclophosphamide, sdriamycin, vincristine/ ifosfamide, etoposide) is a preferable regimen in patients with peripheral PNET and was also used in the current study.
3,21 Laskar et al. recommended radiotherapy sessions as treatment options postoperatively when either gross or microscopic margins were positive for the disease or the tumor showed resistance to chemotherapy. 22 The timing of the postoperative radiotherapy session is also debatable. Laskar et al. 22 advocated the radiotherapy session within 6 to 10 weeks postoperatively, whereas, contrary to this claim, Schuck et al. 23 found no significant difference with further delays. In the current study, radiotherapy was used only in one case after it had a second local recurrence.
Bakhshi et al. 7 treated all patients with neoadjuvant chemotherapy followed by exenteration in 2 cases and radiotherapy and adjuvant chemotherapy in 5 cases. Complete remission was achieved in 3 of the 6 cases at the end of therapy, with globe salvage in 3 cases and vision salvage in 2 cases. In all of our cases, local excision of the tumor was the first choice of treatment and the globe was spared. The only ocular morbidity noted in the current series was in case 2 due to significant tumor involvement of the optic nerve and medial rectus muscle.
Experimental studies have shown retinoic acid derivatives, antivascular endothelial growth factors, and anti-insulin growth factors as promising treatment options for peripheral PNET. [24] [25] [26] [27] [28] Because peripheral PNETs are aggressive and rapidly progressing tumors, the survival rate is generally poor due to distant metastasis and local spread. 4 Kushner et al. studied extracranial primitive neuroectodermal tumors greater than 5 cm and concluded the progression-free survival rate was 25% at 2 years. 29 Romero et al. showed that orbital peripheral PNET is less aggressive in nature; 7 of the studied patients (41%) were alive for at least 30 months. 4 Three of our 4 cases have not shown any progression over a period of 36 months to date, whereas the fourth had recurrence within 1 year of the surgery and chemotherapy.
Based on our observation, we believe that most orbital peripheral PNETs present as well-defined masses on both imaging and perioperatively and are easily removed surgically. This apparently disguised "benign profile" may prove deceptive, but the shorter duration of symptoms (not more than 6 months in all of our cases) remains a strong reminder of the malignant nature of the lesion. 
